

RECEIVED  
CENTRAL FAX CENTER

JUL 27 2006

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office  
in accordance with 37 CFR § 1.8(d) on the date indicated.

Kevin Zielen  
Name

July 27, 2006  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Thomas R. Cech et al.

Art Unit: 1634

Filing Date: November 22, 2000

Examiner: Bradley L. Sisson, Ph.D.

Serial No: 09/721,506

Docket: 015389-002616US; 018-210c

Title: NUCLEIC ACIDS ENCODING HUMAN  
TELOMERASE REVERSE TRANSCRIPTASE  
AND RELATED HOMOLOGS

## DECLARATION UNDER 37 CFR § 1.56

Commissioner for Patents  
Alexandria VA 22313

Dear Sir,

Other U.S. patents and pending non-provisional patent applications owned or co-owned by Geron Corporation that claim protein and/or nucleic acid sequences of telomerase reverse transcriptase and/or the use of such sequences are listed in the following table.

The table includes pending applications in which there is one or more adverse decisions by another examiner that have not yet been resolved in applicants' favor. Such applications are indicated in the right-most column of the table as being subject to *rejection*.

PATENT  
 USSN 09/721,506  
 002616US; 018-210c

USSN	Docket	Title	Status
08/851,843	018/178P1	Telomerase	U.S. Pat. No. 6,093,809
08/854,050	018/179P	Novel Telomerase	U.S. Pat. No. 6,261,836
08/912,951	018/195P1	Telomerized Mammalian Cells Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic Methods	U.S. Pat. No. 6,475,789
08/974,549	018/206P1	Telomerase Catalytic Subunit	U.S. Pat. No. 6,166,178
08/974,584	018/206P2	Functional Homologs of Human Telomerase Reverse Transcriptase Containing the Telomerase T Motif	RCE; non-final rejection under 35 USC § 112 ¶ 1 written description requirement; § 112 ¶ 2; § 102; and obviousness-type double patenting
09/042,460	019/224P	Mouse Telomerase Reverse Transcriptase	U.S. Pat. No. 6,767,719
09/052,919	018/208P3	Antisense Compositions For Detecting And Inhibiting Telomerase Reverse Transcriptase	U.S. Pat. No. 6,444,650
09/128,354	018/257P	Human Telomerase Catalytic Subunit Variants	U.S. Pat. No. 6,337,200
09/244,438	019/246P	Telomerase Promoter Driving Expression of Therapeutic Gene Sequences	U.S. Pat. No. 6,777,203
09/402,181	018/206US	Promoter For Telomerase Reverse Transcriptase	U.S. Pat. No. 6,610,839
09/430,323	018/061C	Novel Telomerase	U.S. Pat. No. 6,309,867
09/432,503	018/063C	Reducing Tissue Damage Due to Impaired Replication Using a Vector for Expressing Telomerase Reverse Transcriptase	RCE; non-final rejection under 35 USC § 112 ¶ 1 enablement requirement
09/438,486	018/062C	Gene for Human Telomerase Reverse Transcriptase and Telomerase Variants	U.S. Pat. No. 6,927,285
09/615,039	019/251C	Oncolytic Virus that Replicates in Cells Expressing Telomerase Reverse Transcriptase	RCE; non-final rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; § 112 ¶ 2; § 102, § 103; and obviousness-type double patenting
09/675,321	081/002C	Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer	U.S. Pat. No. 6,440,735
09/721,456	018/211C	Cells Immortalized with Telomerase Reverse Transcriptase for Use in Drug Screening	U.S. Pat. No. 6,817,110


PATENT  
 USSN 09/721,506  
 002616US; 018-210c

USSN	Docket	Title	Status
09/721,477	018/209C	Immunogenic Nucleic Acid Sequences of Human Telomerase Reverse Transcriptase	RCE; non-final rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; § 112 ¶ 2; § 102, § 103; and obviousness-type double patenting
09/766,253	018/180C	Method for Identifying Nucleotide Sequences Encoding Telomerase Protein	U.S. Pat. No. 6,808,880
09/843,676	018/181C	Telomerase Peptides and Immunogenic Compositions	U.S. Pat. No. 7,056,513
09/953,052	018/251D	Methods for Inhibiting Telomerase Using Antisense Oligonucleotides Against Telomerase Catalytic Component	U.S. Pat. No. 6,627,619
09/990,080	018/258C	Inactive Variants of the Human Telomerase Catalytic Subunit	Allowed; issue fee paid
10/044,539	018/212C	Mammalian Cells that have Increased Proliferative Capacity	Allowed; issue fee due
10/044,692	018/213C	Nucleic Acid Vaccine for Eliciting an Immune Response Against Telomerase Reverse Transcriptase	Non-final rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; and obviousness-type double patenting
10/053,758	018/183C	Antibody to Telomerase Reverse Transcriptase	RCE; non-final rejection under 35 USC § 112 ¶ 1 written description requirement
10/054,295	018/184C	Vectors for Expressing Telomerase Reverse Transcriptase in Mammalian Cells	U.S. Pat. No. 6,921,684
10/054,611	018/182C	Methods for Detecting Nucleic Acids Encoding Human Telomerase Reverse Transcriptase	U.S. Pat. No. 7,005,262
10/208,243	081/003P	Method for Identifying and Killing Cancer Cells	Non-final rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; and obviousness-type double patenting
10/637,443	018/252D	Identifying and Testing Antisense Oligonucleotides that Inhibit Telomerase Reverse Transcriptase	Non-final rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; and 112 ¶ 2
10/674,836	082/103C	Cancer Therapy Using the Telomerase Promoter	No examination on the merits

PATENT  
USSN 09/721,506  
002616US; 018-210c

USSN	Docket	Title	Status
10/862,698	019/225D	Protein and Peptide Fragments from Mouse Telomerase Reverse Transcriptase	RCE; non-final rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; § 102; and § 103
10/877,022	018/223C	Treating Cancer Using a Telomerase Vaccine	No examination on the merits
10/877,124	018/221C	Vector Encoding Inactivated Telomerase for Treating Cancer	No examination on the merits
10/877,146	018/222C	Vaccine Containing the Catalytic Subunit of Telomerase for Treating Cancer	No examination on the merits
11/207,078	018/260C	Sequence of Telomerase Reverse Transcriptase, and Products Derived Therefrom for Conducting Clinical Assays, Immortalizing Cells, Screening Drugs, Treating Cancer, and for Other Commercial Purposes	No examination on the merits
11/411,604	019/252D	Telomerase Promoter Sequences for Screening Telomerase Modulators	No examination on the merits
11/413,838	081/004D	Cellular Telomerase Vaccine and Its Use for Treating Cancer	No examination on the merits

Respectfully submitted,



J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
Telephone: (650) 473-7715  
Fax: (650) 473-8654

July 27, 2006